BriaCell Therapeutics Cor...
(BCTX)
undefined
undefined%
At close: undefined
0.66
-0.87%
Pre-market Dec 16, 2024, 04:33 AM EST
Company Description
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer.
Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer.
The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
BriaCell Therapeutics Corp.
| Country | CA |
| IPO Date | Mar 14, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Dr. William V. Williams M.D. |
Contact Details
Address: Bellevue Centre West Vancouver, BC CA | |
| Website | https://www.briacell.com |
Stock Details
| Ticker Symbol | BCTX |
| Exchange | NASDAQ |
| Fiscal Year | August - July |
| Reporting Currency | USD |
| CIK Code | 0001610820 |
| CUSIP Number | 10778Y302 |
| ISIN Number | CA1079301091 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. William V. Williams M.D. | Chief Executive Officer, President & Director |
| Gadi Levin B.Com., C.A., CPA, M.B.A. | Chief Financial Officer & Corporate Secretary |
| Dr. Charles Louis Wiseman FACP, M.D. | Founder, Principal Research Advisor & Member of Scientific Advisory Board |
| Dr. Giuseppe Del Priore M.D., M.P.H., MPH | Chief Medical Officer |
| Dr. Miguel A. Lopez-Lago Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 13, 2024 | 8-K | Current Report |
| Dec 12, 2024 | 424B5 | Filing |
| Dec 12, 2024 | SC 13D/A | [Amend] Filing |
| Dec 11, 2024 | 424B5 | Filing |
| Dec 10, 2024 | SC 13D/A | [Amend] Filing |
| Dec 05, 2024 | SC 13D/A | [Amend] Filing |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 01, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 10-K | Annual Report |